4/A//SEC Filing
Jayne David R.W. 4/A
Accession 0001628280-22-018767
CIK 0001600620other
Filed
Jul 10, 8:00 PM ET
Accepted
Jul 11, 6:16 AM ET
Size
7.1 KB
Accession
0001628280-22-018767
Insider Transaction Report
Form 4/AAmended
Jayne David R.W.
Director
Transactions
- Exercise/Conversion
Common Stock
2022-05-18$3.62/sh+10,000$36,200→ 40,000 total - Exercise/Conversion
Stock Option (right to buy)
2022-05-18−10,000→ 0 totalExercise: $3.62Exp: 2027-02-16→ Common Stock (10,000 underlying)
Footnotes (2)
- [F1]Converted to U.S. dollars based on the average daily exchange rate of the Bank of Canada reported on the grant date.
- [F2]The shares subject to the option are fully vested and immediately exercisable. They vested in twelve equal monthly installments from the grant date.
Documents
Issuer
Aurinia Pharmaceuticals Inc.
CIK 0001600620
Entity typeother
Related Parties
1- filerCIK 0001838242
Filing Metadata
- Form type
- 4/A
- Filed
- Jul 10, 8:00 PM ET
- Accepted
- Jul 11, 6:16 AM ET
- Size
- 7.1 KB